Pfizer shows profit growth from cost cuts and steadier COVID sales
U.S. drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Tuesday, helped by cost-cutting efforts and better-than-expected sales of its COVID vaccine.
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales
Pfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of 48 cents per share. The company had recorded earnings of 10 cents per share in the year-ago quarter.
Pfizer Earnings Top Estimates After Cost Cuts
Pfizer reported better than expected quarterly profits Tuesday behind cost cuts and growth in some non-Covid-related products in
Pfizer beats profit estimates on heart disease drug, COVID vaccine sales
(Reuters) -Drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Thursday, boosted by cost-cutting, a smaller-than-feared drop in sales of its COVID-19 vaccine and strong demand for its heart drug Vyndaqel.
Pfizer stock climbs on Q4 revenue and earnings beat, reaffirmed guidance
We remain confident in our ability to return to pre-pandemic operating margins in the coming years,” said Pfizer CFO David Denton.
Pfizer Beats Q4 Revenue, EPS Estimates
Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.
Pfizer beats profit estimates on cost cuts, COVID vaccine sales
(Reuters) -Drugmaker Pfizer posted a better than expected fourth quarter profit on Thursday, helped by cost cuts and a smaller-than-feared drop in sales of its COVID-19 vaccine. "Our revenue volatility is largely in the past as COVID-related uncertainties have diminished,
Pfizer 4Q Revenue Beat Leads to Swing to Profit
Revenue rose to $17.76 billion from $14.57 billion. Analysts polled by FactSet had expected $17.35 billion. Chief Financial Officer David Denton said Pfizer remains on track to deliver $1.5 billion of net cost savings by the end of 2027,
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price.
Pfizer Stock Rises on Fourth-Quarter Earnings Beat and Reaffirmed Guidance
The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.
Pfizer’s Covid boost overshadowed by Kennedy threat to vaccines
Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's ...
Crain's New York13h
Pfizer gets unexpected boost from Covid vaccine and pill
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...
FiercePharma14h
Pfizer harnesses COVID fluctuations to clinch Q4 gains as RSV vaccine sales plummet
After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely ...
Smaller US winter COVID wave adds pressure to Pfizer turnaround
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...
Politifact5d
No, Pfizer didn’t release a new list of COVID-19 vaccine side effects
"Pfizer just released its list of side effects of its COVID-19 vaccine," multiple Facebook posts said Jan. 26 and 27. The posts included a purported list of 46 Pfizer-BioNtech COVID-19 vaccine side ...
Pfizer CEO: Our stock is very cheap with lots of upside potential
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...
Left Foot Forward14h
Shadow foreign secretary repeats false claim covid vaccine was ‘one of the Brexit benefits’
Tory shadow foreign secretary Wendy Morton has incorrectly said that Britain becoming the first Western country to approve a ...
devdiscourse17h
Key Developments in Global Health: Merck, Pfizer, and Innovative Vaccines
This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...